Peripheral blood MR1 tetramer‐positive mucosal‐associated invariant T‐cell function is modulated by mammalian target of rapamycin complex 1 in patients with active tuberculosis

• Published in: Immunology Vol. 173; no. 3; pp. 497 - 510
• Main Authors: Zhou, Chao‐Ying, Yang, Ya‐Long, Han, Zhen‐Yu, Chen, Yao‐Xin, Liu, Hong‐Lin, Fan, Ke, Li, Ming‐Chong, Tu, Si‐Hang, Wen, Qian, Zhou, Xin‐Ying, Ma, Li
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.11.2024
• Subjects: Adult; Antigen-presenting cells; Biological effects; Blood; CD4 antigen; CD8 antigen; CD8-Positive T-Lymphocytes - immunology; Cell proliferation; Cytokines - metabolism; Effectiveness; Female; Histocompatibility Antigens Class I - immunology; Histocompatibility Antigens Class I - metabolism; Humans; Immune response; Immune system; Immunotherapy; Invariants; Lymphocyte Activation; Lysis; Male; Mechanistic Target of Rapamycin Complex 1 - metabolism; Middle Aged; Minor Histocompatibility Antigens - immunology; Minor Histocompatibility Antigens - metabolism; MR1 tetramer; mTORC1; Mucosa; Mucosal-Associated Invariant T Cells - immunology; Mucosal-Associated Invariant T Cells - metabolism; mucosal‐associated invariant T cells; Mycobacterium tuberculosis - immunology; Peripheral blood; Population studies; Public health; Rapamycin; Reagents; Sirolimus - pharmacology; Therapeutic targets; TOR protein; Tuberculosis; Tuberculosis - immunology; Vaccine efficacy; Young Adult; mucosal‐associated invariant T cells; MR1 tetramer; mTORC1; tuberculosis

Tuberculosis (TB) is still an urgent global public health problem. Notably, mucosal‐associated invariant T (MAIT) cells play an important role in early anti‐TB immune response. Targeted control of them may be an effective method to improve vaccine efficacy and TB treatment. However, the biology and...